Following the Blueprint

After completing an annotated library to bootstrap the development of inhibitors of almost any kinase, Blueprint Medicines has disclosed two test-case inhibitors intended to show how the library can tackle tough targets. The company now is using its genomics platform to identify new targets and patient populations, which will inform future products it develops using its library.

Blueprint launched in 2011 with a $40 million investment from Third Rock Ventures and a plan to shut down overactive kinases in cancer using a two-pronged approach: a library of kinase inhibitors and a target discovery engine focused on the kinome that incorporates genomics, bioinformatics, structural and cellular biology...